These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1393 related items for PubMed ID: 16882940

  • 1. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E, AGO-OVAR, GINECO.
    J Natl Cancer Inst; 2006 Aug 02; 98(15):1036-45. PubMed ID: 16882940
    [Abstract] [Full Text] [Related]

  • 2. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
    du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, Barats JC, Kuhn W, Orfeuvre H, Wagner U, Richter B, Lueck HJ, Pfisterer J, Costa S, Schroeder W, Kimmig R, Pujade-Lauraine E, Arbeitsgemeinschaft Gynaekologische Onkologie, Ovarian Cancer Study Group, Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
    J Clin Oncol; 2006 Mar 01; 24(7):1127-35. PubMed ID: 16505432
    [Abstract] [Full Text] [Related]

  • 3. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
    Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA.
    J Natl Cancer Inst; 2010 Oct 20; 102(20):1547-56. PubMed ID: 20937992
    [Abstract] [Full Text] [Related]

  • 4. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
    J Clin Oncol; 2006 Feb 01; 24(4):579-86. PubMed ID: 16446330
    [Abstract] [Full Text] [Related]

  • 5. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
    De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, Marinaccio M, Cartenì G, Manzione L, Febbraro A, De Matteis A, Gasparini G, Valerio MR, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S.
    J Clin Oncol; 2004 Jul 01; 22(13):2635-42. PubMed ID: 15226331
    [Abstract] [Full Text] [Related]

  • 6. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
    Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, Ostermann H, Hinke A, Ledermann JA, AGO-Ovar/AIO, EBMT.
    J Clin Oncol; 2007 Sep 20; 25(27):4187-93. PubMed ID: 17698804
    [Abstract] [Full Text] [Related]

  • 7. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB, Scottish Gynaecological Cancer Trials Group.
    J Natl Cancer Inst; 2004 Nov 17; 96(22):1682-91. PubMed ID: 15547181
    [Abstract] [Full Text] [Related]

  • 8. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Bauknecht T, Warm M, Schroeder W, Olbricht S, Nitz U, Jackisch C.
    Semin Oncol; 1997 Aug 17; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [Abstract] [Full Text] [Related]

  • 9. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Aug 17; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 10. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R, Pfisterer J.
    Gynecol Oncol; 2009 Aug 17; 114(2):199-205. PubMed ID: 19446314
    [Abstract] [Full Text] [Related]

  • 11. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Warm M, Bauknecht T, Schröder W, Olbricht S, Nitz U, Jackisch C.
    Semin Oncol; 1997 Oct 17; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [Abstract] [Full Text] [Related]

  • 12. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
    Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A.
    J Clin Oncol; 2010 Jul 10; 28(20):3323-9. PubMed ID: 20498395
    [Abstract] [Full Text] [Related]

  • 13. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, Bafaloukos D, Karphathios S, Papakostas P, Bamia C, Fountzilas G.
    Semin Oncol; 1997 Oct 10; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [Abstract] [Full Text] [Related]

  • 14. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
    Prince HM, Rischin D, Quinn M, Allen D, Planner R, Neesham D, Gates P, Davison J.
    Gynecol Oncol; 2001 May 10; 81(2):216-24. PubMed ID: 11330952
    [Abstract] [Full Text] [Related]

  • 15. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
    Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, Ulm K, Hessler S, Gatzemeier U.
    Lung Cancer; 2006 Jul 10; 53(1):67-75. PubMed ID: 16713013
    [Abstract] [Full Text] [Related]

  • 16. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S, EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm.
    J Natl Cancer Inst; 2003 Jan 15; 95(2):113-25. PubMed ID: 12529344
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
    Gordon AN, Asmar L, Messing MJ, Street DG, Pippitt CH, Bailey CL, Savage J, Young JA.
    Gynecol Oncol; 2004 Aug 15; 94(2):533-9. PubMed ID: 15297200
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
    Gronlund B, Hansen HH, Høgdall C, Engelholm SA.
    Cancer; 2002 Oct 15; 95(8):1656-62. PubMed ID: 12365013
    [Abstract] [Full Text] [Related]

  • 19. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
    Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O, Conte P, After 6 Italian Cooperative Group.
    J Clin Oncol; 2009 Oct 01; 27(28):4642-8. PubMed ID: 19704064
    [Abstract] [Full Text] [Related]

  • 20. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S, Breda E, Scambia G, Pisano C, Zagonel V, Lorusso D, Greggi S, De Vivo R, Ferrandina G, Gallo C, Perrone F.
    Crit Rev Oncol Hematol; 2008 Jun 01; 66(3):229-36. PubMed ID: 18243011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.